Atlas Trials

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Clinical trial NCT03737812 · COMPLETED

Trial details

NCT number
NCT03737812
Sponsor
AbbVie
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Sclerosis (MS)
Start date
2019-02-27
Primary completion
2021-01-15
Enrollment
123

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.